Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Ssharfaei (talk | contribs)
editnews, nocaptcha, Administrators, Widget editors
7,502 edits
Ssharfaei (talk | contribs)
editnews, nocaptcha, Administrators, Widget editors
7,502 edits
No edit summary
Line 1: Line 1:
==Thrombocytopenia Differential Diagnosis==
==Differentiating Pancytopenia from Other Diseases==
'''Differentiating the diseases that can cause thrombocytopenia:'''
* Pancytopenia must be differentiated from a pseudo-syndromes like pseudo-thrombocytopenia, which is a laboratory artifact from platelet clumping.
* There are no other mimickers of pancytopenia, as the diagnosis can be unequivocally established by laboratory testing ([[complete blood count]]).
 
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="5" |Category
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! colspan="2" rowspan="5" |Condition
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="5" |Mechanism
! colspan="3" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mechanism
! colspan="3" rowspan="4" |Mechanism
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! rowspan="5" |Inherited
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! rowspan="5" |Acquried
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="10" |Clinical manifestations
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
! colspan="10" rowspan="2" |Para−clinical findings
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! rowspan="4" |Age range
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! rowspan="4" |History
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
| colspan="4" rowspan="2" |Signs
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="9" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! rowspan="2" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="3" |CBC
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" |PT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! rowspan="2" |PTT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! rowspan="2" |BT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! rowspan="2" |UA
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
!Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
!Platelet destruction in bloodstream
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
!Platelet destruction in spleen/liver
sequestration/
!Plt
redistribution
!HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
!WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|-
|-
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematology
! rowspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic disorders
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
! align="center" style="background:#DCDCDC;" |Myelodysplastic syndromes (MDS)
! align="center" style="background:#DCDCDC;" + |Myelodysplastic syndromes
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + |
* Bone marrow infiltration
* Ineffective hematopoiesis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
|-
! align="left" style="background:#DCDCDC;" |Malignancies such as:
* Acute leukemias
* Chronic leukemias
* Multiple myeloma
* Metastatic cancer
| align="left" style="background:#F5F5F5;" + |
* Bone marrow infiltration
* Ineffective hematopoiesis
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Aplastic anemia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Acute leukemia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 141: Line 111:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Paroxysmal nocturnal hemoglobinuria (PNH)
! align="center" style="background:#DCDCDC;" |Myelofibrosis
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 171: Line 140:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="3" align="center" style="background:#DCDCDC;" + |Thrombotic microangiopathy (TMA)
! align="center" style="background:#DCDCDC;" |Fanconi anemia
! align="center" style="background:#DCDCDC;" + |Thrombotic thrombocytopenic purpura (TTP)
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 202: Line 168:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Hemolytic uremic syndrome (HUS)
! align="center" style="background:#DCDCDC;" |Aplastic anemia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 232: Line 197:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |DIC
! align="center" style="background:#DCDCDC;" |Paroxysmal nocturnal hemoglobinuria
| align="center" style="background:#F5F5F5;" + |Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 262: Line 225:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders
! align="center" style="background:#DCDCDC;" |Disseminated intravascular coagulation
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
| align="center" style="background:#F5F5F5;" + |Consumption
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 293: Line 253:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" |Dyskeratosis congenital/telomere biology disorders
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 323: Line 281:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
! align="center" style="background:#DCDCDC;" |Shwachman-Diamond syndrome
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 353: Line 309:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
| align="center" style="background:#F5F5F5;" + |
sequestration/
| align="center" style="background:#F5F5F5;" + |
redistribution
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/
| align="center" style="background:#F5F5F5;" + |
Rheumatology
| align="center" style="background:#F5F5F5;" + |
! align="center" style="background:#DCDCDC;" |SLE
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 413: Line 370:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Alport syndrome
! align="center" style="background:#DCDCDC;" |Felty syndrome
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 443: Line 398:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
! align="center" style="background:#DCDCDC;" |Wiskott Aldrich syndrome
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Nutrient deficiencies
! align="center" style="background:#DCDCDC;" + |Folate, vitamin B12, copper
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 498: Line 425:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
!
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! align="center" style="background:#DCDCDC;" |GATA2 deficiency
!Category
! colspan="2" |Condition
!Mechanism
!Decreased platelet production
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!Inherited
!Acquried
!Age range
!History
!Severity
!Fever
!Rash
!Bleeding
!BP
!Splenomegaly
!Jaundice
!Other signs
!Plt
!HB
!WBC
!PBS
!Bone marrow exam
!PT
!PTT
!BT
!UA
!Imaging
!Gold standard
!Associated findings
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 568: Line 454:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE)
! align="center" style="background:#DCDCDC;" |Hemophagocytic lymphohistiocytosis (HLH)
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 598: Line 482:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS)
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI disorders
| align="center" style="background:#F5F5F5;" + |Autoantibody-mediated syndrome
! align="center" style="background:#DCDCDC;" |Portal hypertension/cirrhosis
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Splenomegally
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 628: Line 512:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Felty's syndrome
! align="center" style="background:#DCDCDC;" |Storage diseases (eg, Gaucher)
| align="center" style="background:#F5F5F5;" + |Splenomegaly
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Splenomegaly
| align="center" style="background:#F5F5F5;" + |
* Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 658: Line 542:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection-induced
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! align="center" style="background:#DCDCDC;" + |Sepsis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
| align="center" style="background:#F5F5F5;" + |Direct bone marrow suppression
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |+
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
| align="center" style="background:#F5F5F5;" + |+
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
| align="center" style="background:#F5F5F5;" + |
sequestration/
| align="center" style="background:#F5F5F5;" + |
redistribution
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
| align="center" style="background:#F5F5F5;" + |Immune thrombocytopenia
! align="center" style="background:#DCDCDC;" |Sepsis
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
* Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 720: Line 603:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Tick-borne infection
! align="center" style="background:#DCDCDC;" |Viral infection such as HIV, hepatitis, Epstein-Barr virus
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Marrow suppression
| align="center" style="background:#F5F5F5;" + |+
* Splenomegaly
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 750: Line 633:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional
! align="center" style="background:#DCDCDC;" + |HIV
! align="center" style="background:#DCDCDC;" |Megaloblastic anemia
| align="Left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Direct toxicity to megakaryocytes
* Ineffective hematopoiesis
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
* Secondary opportunistic infections
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 814: Line 663:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! align="center" style="background:#DCDCDC;" |Excessive alcohol
! align="center" style="background:#DCDCDC;" + |Malaria
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Ineffective hematopoiesis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 845: Line 692:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Babesiosis
! align="center" style="background:#DCDCDC;" |Other (eg, copper deficiency, zinc toxicity)
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Ineffective hematopoiesis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 875: Line 721:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! align="center" style="background:#DCDCDC;" |Malnutrition
!Category
| align="left" style="background:#F5F5F5;" + |
! colspan="2" |Condition
* Ineffective hematopoiesis
!Mechanism
!Decreased platelet production
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!Inherited
!Acquried
!Age range
!History
!Severity
!Fever
!Rash
!Bleeding
!BP
!Splenomegaly
!Jaundice
!Other signs
!Plt
!HB
!WBC
!PBS
!Bone marrow exam
!PT
!PTT
!BT
!UA
!Imaging
!Gold standard
!Associated findings
|-
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medication/toxicity
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
! align="left" style="background:#DCDCDC;" + |
* Antibiotics
** Sulfonamides
** Ampicillin
** Piperacillin
** Vancomycin
** Rifampin
* Older antiepileptic agents
** carbamazepine
** Phenytoin
* Quinine
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 949: Line 750:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications
| align="center" style="background:#F5F5F5;" + |
! align="left" style="background:#DCDCDC;" |Medications such as:
| align="center" style="background:#F5F5F5;" + |
* Cytotoxic drugs
| align="center" style="background:#F5F5F5;" + |+
* Idiosyncratic reactions to medications
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Immune destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,009: Line 782:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent myelosuppression
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
| align="center" style="background:#F5F5F5;" + |+
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
| align="center" style="background:#F5F5F5;" + |
sequestration/
| align="center" style="background:#F5F5F5;" + |
redistribution
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! align="center" style="background:#DCDCDC;" + |OTC agents
! align="center" style="background:#DCDCDC;" + |Quinine-containing beverages
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Portal hypertension
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!Category
! colspan="2" |Condition
!Mechanism
!Decreased platelet production
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!Inherited
!Acquried
!Age range
!History
!Severity
!Fever
!Rash
!Bleeding
!BP
!Splenomegaly
!Jaundice
!Other signs
!Plt
!HB
!WBC
!PBS
!Bone marrow exam
!PT
!PTT
!BT
!UA
!Imaging
!Gold standard
!Associated findings
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma
| align="center" style="background:#F5F5F5;" + |Platelet destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm
| align="center" style="background:#F5F5F5;" + |Platelet destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass
| align="center" style="background:#F5F5F5;" + |Platelet destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Post-transfusion purpura
| align="center" style="background:#F5F5F5;" + |Immune mediated platelet destruction
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|}
|}
<references />

Revision as of 19:43, 6 September 2018

Differentiating Pancytopenia from Other Diseases

  • Pancytopenia must be differentiated from a pseudo-syndromes like pseudo-thrombocytopenia, which is a laboratory artifact from platelet clumping.
  • There are no other mimickers of pancytopenia, as the diagnosis can be unequivocally established by laboratory testing (complete blood count).
Category Condition Etiology Mechanism Congenital Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings Imaging
Appearance Fever Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT UA
Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Plt HB WBC
Hematologic disorders Myelodysplastic syndromes (MDS)
  • Bone marrow infiltration
  • Ineffective hematopoiesis
Malignancies such as:
  • Acute leukemias
  • Chronic leukemias
  • Multiple myeloma
  • Metastatic cancer
  • Bone marrow infiltration
  • Ineffective hematopoiesis
 + + +
Myelofibrosis
  • Bone marrow infiltration
 +
Fanconi anemia +
Aplastic anemia
  • Immune destruction
 +
Paroxysmal nocturnal hemoglobinuria Immune destruction +
Disseminated intravascular coagulation Consumption
Dyskeratosis congenital/telomere biology disorders
Shwachman-Diamond syndrome +
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings
Immunology/

Rheumatology

SLE
Felty syndrome
Wiskott Aldrich syndrome +
GATA2 deficiency +
Hemophagocytic lymphohistiocytosis (HLH) +
GI disorders Portal hypertension/cirrhosis
  • Splenomegally
Storage diseases (eg, Gaucher)
  • Splenomegaly
  • Bone marrow infiltration
 + +
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings
Infections Sepsis
  • Bone marrow infiltration
Viral infection such as HIV, hepatitis, Epstein-Barr virus
  • Marrow suppression
  • Splenomegaly
 + +
Nutritional Megaloblastic anemia
  • Ineffective hematopoiesis
 +
Excessive alcohol
  • Ineffective hematopoiesis
Other (eg, copper deficiency, zinc toxicity)
  • Ineffective hematopoiesis
Malnutrition
  • Ineffective hematopoiesis
Medications Medications such as:
  • Cytotoxic drugs
  • Idiosyncratic reactions to medications
  • Immune destruction
 +
Category Condition Etiology Bone marrow infiltration Bone marrow failure Destruction/

sequestration/ redistribution

Congenital Acquried Demography History Appearance Fever Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT UA Imaging Gold standard Associated findings
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_sadaf&oldid=1493274"